10-Q: Cancer Capital Corp. Reports Q1 2024 Results: No Revenue, Continued Losses, and Going Concern Uncertainty

Cancer Capital Corp. reported no revenue and a net loss of $15,939 for the quarter ended March 31, 2024, with substantial doubt about its ability to continue as a going concern.

Summary

• Cancer Capital Corp. filed its Form 10-Q for the quarter ended March 31, 2024.
• The company reported no revenue for the quarter.
• The net loss for the quarter was $15,939, compared to a net loss of $11,408 for the same period in 2023.
• General and administrative expenses increased to $10,050 from $5,699 year-over-year.
• The company's cash position decreased from $16,157 at the end of 2023 to $12,657 at the end of Q1 2024.
• Total liabilities increased to $447,988 from $465,549 at the end of 2023.
• The company has a significant accumulated deficit of $518,531.
• Management expresses substantial doubt about the company's ability to continue as a going concern, dependent on securing financing and a business combination.
• The company is seeking a merger or acquisition with an operating company to generate revenue.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of segregation of duties.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the company's lack of revenue, increasing losses, going concern uncertainty, and ineffective disclosure controls.

Negatives

• Cancer Capital Corp. has not recorded any revenues since inception.
• The company is experiencing negative cash flows from operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures are not effective due to a lack of segregation of duties.
• The company is dependent on financing to continue operations.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company is dependent on securing financing, which is not guaranteed.
• The company faces risks inherent in combining with a financially unstable or early-stage company.
• The selection of a business opportunity is complex and risky.
• Issuance of shares in a business combination could result in significant dilution to existing stockholders.
• The company's lack of revenue generation poses a significant risk.
• The company's disclosure controls and procedures are ineffective.

Future Outlook

The company's future is dependent on securing financing and completing a business combination to generate revenue. Management anticipates incurring additional costs related to Exchange Act reporting and believes they can meet these costs through funds provided by management, significant stockholders, and/or third parties.

Management Comments

• Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future.
• Our plan is to combine with an operating company to generate revenue.

Industry Context

Given the company's lack of revenue and dependence on external financing, it is operating in a high-risk environment, common among shell companies seeking a business combination. The company's success hinges on identifying and integrating with a viable operating business.

Comparison to Industry Standards

• It is difficult to compare Cancer Capital Corp.'s performance to industry standards due to its lack of operations and revenue.
• Many shell companies operate with minimal assets and significant liabilities while seeking a target for acquisition.
• The company's financial situation is not uncommon for companies in the early stages of seeking a business combination.

Legal Proceedings

• The company knows of no material, existing or pending legal proceedings against it.

Related Party Transactions

• During the three months ended March 31, 2024, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $1,500, resulting in the Company owing the shareholder $7,500 at March 31, 2024.
• During the three months ended March 31, 2024, a shareholder loaned the Company $0 by related parties.
• Notes payable related party at March 31, 2024, and December 31, 2023, were $164,125 and $164,125, respectively.
• Accrued interest at March 31, 2024, and December 31, 2023, was $93,436 and $90,153, respectively.

Stakeholder Impact

• Shareholders face significant risk of dilution if the company issues more shares.
• The company's employees (if any) face uncertainty due to the company's going concern issues.
• Creditors face risk due to the company's limited assets and ability to repay debts.

Next Steps

• The company intends to seek a suitable business opportunity and acquire or merge with such company.
• The company anticipates incurring additional costs related to the filing of Exchange Act reports.

Key Dates

Keywords

going concern, business combination, merger, acquisition, financing, net loss, liabilities, cash flow, revenue, Cancer Capital Corp